A phase II, open-label, non-randomized, multi-center pilot study of intravenous Taxol [paclitaxel], carboplatin, bevacizumab [Avastin] given every 21 days in patients with newly diagnosed stage III/IV epithelial ovarian, fallopian tube or peritoneal cancer

Trial Profile

A phase II, open-label, non-randomized, multi-center pilot study of intravenous Taxol [paclitaxel], carboplatin, bevacizumab [Avastin] given every 21 days in patients with newly diagnosed stage III/IV epithelial ovarian, fallopian tube or peritoneal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Aug 2007 The expected completion date for this trial is now 1 Aug 2005.
    • 02 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top